Long acting injectable HIV treatment provides an alternative to daily oral antiretroviral medication for eligible people living with HIV. These treatments use injections administered at scheduled intervals to maintain medication levels that suppress HIV replication. Injectable options can reduce the need to take pills every day, although regular clinic appointments remain essential. Eligibility depends on factors such as viral suppression.
Long acting injectable HIV treatments contain antiretroviral medicines formulated to remain active in the body for extended periods. Unlike conventional oral treatment, which generally requires daily dosing, these injections are administered according to a planned schedule. The most established long acting treatment combination contains cabotegravir and rilpivirine, marketed as Cabenuva in the United States.
Cabotegravir belongs to a class of medicines called integrase strand transfer inhibitors, while rilpivirine is a non-nucleoside reverse transcriptase inhibitor. Together, they target different stages of the HIV replication process.
The combination is generally used as a complete treatment regimen for eligible adults and certain adolescents whose HIV is already virologically suppressed. It is not intended for everyone starting HIV treatment, and healthcare professionals must assess whether switching is appropriate.
Common considerations include:
Dosing schedules: Injections are typically administered every month or every two months, depending on the prescribed regimen and local approval.
Treatment eligibility: Patients generally need sustained viral suppression, no history of treatment failure, and no known or suspected resistance to cabotegravir or rilpivirine.
Previous treatment: Clinicians review existing medications, treatment history, and potential drug interactions before recommending injectable therapy.
Oral lead in: An optional oral lead in may be used to assess tolerability before injections, depending on the product instructions and clinical circumstances.
Other formulations: Long acting cabotegravir alone is also approved in several countries, including the United States, for HIV prevention as pre-exposure prophylaxis, or PrEP. It is not an HIV treatment regimen by itself.
Availability, eligibility, and approved dosing schedules can vary by country, so local prescribing guidance should be followed.
Long acting injectable therapy can offer practical advantages for people who find daily tablets difficult to manage. Scheduled injections may help reduce the burden of daily medication routines and provide greater flexibility in everyday life. However, successful treatment depends on attending appointments on time and following the prescribed plan.
As with all antiretroviral medicines, injectable treatment can cause side effects and requires ongoing medical supervision. Injection site reactions are among the most frequently reported effects and may include pain, swelling, redness, or discomfort. Other possible effects include headache, fever, fatigue, nausea, and sleep disturbances.
Important factors to consider include:
Injection appointments: Missing or delaying an injection can reduce medication protection against HIV replication. Patients should contact their healthcare provider promptly if an appointment may be missed.
Viral load monitoring: Blood tests help determine whether the treatment continues to suppress HIV effectively.
Drug interactions: Certain medicines, including some anticonvulsants, rifamycin antibiotics, and St John's wort, can interact with treatment and may reduce medication levels.
Resistance concerns: If treatment fails and HIV develops resistance, future treatment choices may become more limited.
Long medication persistence: These drugs can remain in the body for many months after the final injection. When treatment is discontinued, a clinician must arrange an appropriate alternative antiretroviral regimen to reduce the risk of viral rebound and resistance.
Pregnancy considerations: People who are pregnant, planning pregnancy, or breastfeeding should discuss the potential benefits and risks with their healthcare professional.
Long acting injectable HIV treatment is an important development in HIV care, providing an alternative to daily oral medication for appropriately selected individuals. Understanding treatment eligibility, dosing schedules, possible side effects, and follow up requirements helps patients make informed decisions with their healthcare teams. Regular monitoring and timely injections remain essential for maintaining viral suppression and protecting long term health.